Stifel Downgrades Keryx Biopharmaceuticals (KERX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Brean Capital Downgrades Keryx Biopharmaceuticals (KERX) to Hold
August 2, 2016 6:58 AM EDTBrean Capital downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Buy to Hold.
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $4.72 yesterday.
... MoreFBR Capital Downgrades Keryx Biopharmaceuticals (KERX) to Market Perform
August 2, 2016 6:23 AM EDTFBR Capital downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Outperform to Market Perform with a price target of $7.00 (from $13.00) following news of a production-related interruption in Auryxia supply.
Analyst Christopher James commented, "Yesterday, August 1, Keryx hosted a conference call to review its 2Q16 financial performance and... More
